Britain's GlaxoSmithKline (GSK)
is relatively unusual among drug companies today. Not all that much
revenue is left vulnerable to patent expirations, the company has a deep
pipeline balanced between potential home runs and solid singles and
doubles, and only one drug accounts for more than 10% of pharmaceutical
sales. While the Street has already rewarded Glaxo with a healthy
valuation, there is still a great deal of debate as to the potential of
key pipeline candidates and shareholders could yet see upside here if a
few key drugs exceed expectations.
Click here for the full story:
Better Days Ahead For GlaxoSmithKline
No comments:
Post a Comment